Cohn Lillian, Delamarre Lélia
Laboratory of Molecular Immunology, Rockefeller University , New York, NY , USA.
Genentech , South San Francisco, CA , USA.
Front Immunol. 2014 May 30;5:255. doi: 10.3389/fimmu.2014.00255. eCollection 2014.
Despite significant effort, the development of effective vaccines inducing strong and durable T-cell responses against intracellular pathogens and cancer cells has remained a challenge. The initiation of effector CD8(+) T-cell responses requires the presentation of peptides derived from internalized antigen on class I major histocompatibility complex molecules by dendritic cells (DCs) in a process called cross-presentation. A current strategy to enhance the effectiveness of vaccination is to deliver antigens directly to DCs. This is done via selective targeting of antigen using monoclonal antibodies directed against endocytic receptors on the surface of the DCs. In this review, we will discuss considerations relevant to the design of such vaccines: the existence of DC subsets with specialized functions, the impact of the antigen intracellular trafficking on cross-presentation, and the influence of maturation signals received by DCs on the outcome of the immune response.
尽管付出了巨大努力，但开发能够诱导针对细胞内病原体和癌细胞产生强大而持久的T细胞反应的有效疫苗仍然是一项挑战。效应性CD8(+) T细胞反应的启动需要树突状细胞（DCs）在一个称为交叉呈递的过程中，将内化抗原衍生的肽呈递到I类主要组织相容性复合体分子上。当前提高疫苗效力的一种策略是将抗原直接递送至DCs。这是通过使用针对DCs表面内吞受体的单克隆抗体选择性靶向抗原来实现的。在这篇综述中，我们将讨论与此类疫苗设计相关的考虑因素：具有特定功能的DC亚群的存在、抗原细胞内运输对交叉呈递的影响，以及DCs接收到的成熟信号对免疫反应结果的影响。
